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Abstract 
 
Background: Clinical predictive tools quantify contributions of relevant patient 
characteristics to derive likelihood of diseases or predict clinical outcomes. When 
selecting a predictive tool, for implementation at clinical practice or for recommendation 
in clinical guidelines, clinicians are challenged with an overwhelming and ever growing 
number of tools, most of which have never been implemented or assessed for 
comparative effectiveness. Objective: To develop a comprehensive framework to Grade 
and Assess Predictive tools (GRASP), and provide clinicians with a standardised, evidence-
based system to support their searh for and selection of effective tools. Methods: A 
focused review of literature was conducted to extract criteria along which tools should be 
evaluated. An initial framework was designed and applied to assess and grade five tools: 
LACE Index, Centor Score, Well’s Criteria, Modified Early Warning Score, and Ottawa knee 
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rule. After peer review, by expert clinicians and healthcare researchers, the framework 
was revised and the grading of the tools was updated. Results: GRASP framework grades 
predictive tools based on published evidence across three dimensions: 1) Phase of 
evaluation; 2) Level of evidence; and 3) Direction of evidence. The final grade of a tool is 
based on the highest phase of evaluation, supported by the highest level of positive 
evidence, or mixed evidence that supports positive conclusion. Ottawa knee rule had the 
highest grade since it has demonstrated positive post-implementation impact on 
healthcare. LACE Index had the lowest grade, having demonstrated only pre-
implementation positive predictive performance. Discussion and Conclusion: the GRASP 
framework builds on well-established models and widely accepted concepts to provide 
standardised assessment and evidence-based grading of predictive tools. Unlike other 
methods, GRASP is based on the critical appraisal of published evidence reporting the 
predictive tools’ predictive performance before implementation, potential effect and 
usability during implementation, and their post-implementation impact. Implementing 
the GRASP framework as an online platform will enable clinicians and clinical guidelines 
developers to access detailed information, reported evidence and grades of predictive 
tools. However, keeping the GRASP framework reports up-to-date requires updating tools’ 
assessments and grades when new evidence becomes available. This requires employing 
semi-automated methods for searching and processing new information. 
 
Keywords: Predictive Analytics, Clinical Prediction, Clinical Decision Support, Evidence-
Based Medicine. 
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Background 
 
Modern healthcare is building upon information technology to enhance evidence-
based practice and cost-effectiveness, using clinical decision support (CDS) systems [1-
4]. Based on Shortliffe’s definition, there are three levels of CDS: 1) Managing information, 
2) Focusing users’ attention and 3) Providing patient specific recommendations based on 
the clinical scenario, which usually follow rules and algorithms, cost benefit analysis or 
clinical pathways [5, 6]. Clinical predictive tools, here referred to simply as predictive 
tools, belong to the third level of CDS and include various applications; ranging from the 
simplest manual clinical prediction rules to the most sophisticated machine learning 
algorithms [7, 8]. These research-based applications provide diagnostic, prognostic, or 
therapeutic decision support. They quantify the contributions of relevant patient 
characteristics to derive the likelihood of diseases, predict their courses and possible 
outcomes, or support the decision making on their management [9, 10]. 
 
Why do we need grading and assessment of predictive tools? 
 
When selecting a predictive tool, for implementation at clinical practice or for 
recommendation in clinical practice guidelines, clinicians involved in the decision making 
are challenged with an overwhelming and ever growing number of tools. Many of these 
tools are designed for various clinical contexts and are frequently targeting different 
patient populations [11-13]. Currently, clinicians rely on their previous experience, 
subjective evaluation or recent exposure to predictive tools in making selection decisions. 
Objective methods and evidence-based methods are rarely used in such decisions [14, 
15]. Some clinicians, especially those developing clinical guidelines, search the literature 
for best available evidence, looking for primary studies or systematic reviews on 
predictive tools. However, there are no available methods to objectively summarise or 
interpret such evidence [16, 17].  
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Many clinicians lack the required time and knowledge to evaluate predictive tools, 
assessing their quality or grading their level of evidence, especially as their number and 
complexity have increased tremendously in recent years. This is made worse by the 
complex nature of the evaluation process itself and the variability in the quality of 
published evidence [18-21]. Although most reported tools have been internally validated, 
only some have been externally validated and very few have been implemented and 
studied for their post-implementation impact on healthcare [22, 23]. Various studies and 
reports indicate that there is an unfortunate practice of developing new tools instead of 
externally validating or updating existing ones [10, 24-27]. More importantly, while a few 
pre-implementation studies compare similar predictive tools along some predictive 
performance measures, comparative studies for post-implementation impact or cost-
effectiveness are very rare [28-37]. As a result, there is lack of a reference against which 
predictive tools can be compared or benchmarked [9, 38, 39]. 
 
In addition, decision makers need to consider the usability of a tool, which 
depends on the specific healthcare and IT settings in which it is embedded, and on users’ 
priorities and perspectives [40]. The usability of tools is consistently improved when the 
outputs are actionable or directive [41-44]. Moreover, clinicians are keen to know if a tool 
has been endorsed by certain professional organisations they follow, or recommended by 
specific clinical guidelines they know [25].  
 
Current methods for appraising predictive tools 
   
 Several methods have been proposed to evaluate predictive tools [10, 23, 45-59]. 
However, most of these methods are not based on the critical appraisal of the existing 
evidence but rather examine a certain aspect of each tool or a specific phase of its 
development or implementation, reporting evidence about its predictive performance or 
post-implementation impact. Two exceptions are the TRIPOD statement [60, 61], which 
provides a set of recommendations for the reporting of studies developing, validating, or 
updating predictive tools; and the CHARMS checklist [62], which provides guidance on 
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critical appraisal and data extraction for systematic reviews of predictive tools. Both of 
these methods examine only the pre-implementation predictive performance of the tools, 
ignoring their usability and post-implementation impact. In addition, none of the 
currently available methods provide a grading system to allow for benchmarking and 
comparative effectiveness of tools. 
 
Looking beyond predictive tools, the GRADE framework, grades the quality of 
published scientific evidence and strength of clinical recommendations, in terms of their 
post-implementation impact. GRADE has gained a growing consensus, as an objective and 
consistent method to support the development and evaluation of clinical guidelines, and 
has increasingly been adopted worldwide [63, 64]. Information based on randomised 
controlled trials (RCTs) is considered the highest level of evidence. However, the level of 
evidence could be downgraded due to study limitations, inconsistency of results, 
indirectness of evidence, imprecision, or reporting bias [64-66]. The strength of a 
recommendation indicates the extent to which one can be confident that adherence to the 
recommendation will do more good than harm, it also requires a balance between 
simplicity and clarity [63, 67].  
 
The aim of this study is to develop a comprehensive evidence-based framework 
for grading and assessment of predictive tools. This framework is based on the critical 
appraisal of information provided in the published evidence reporting the evaluation of 
predictive tools. The framework should provide clinicians with standardised objective 
information on predictive tools to support their search for and selection of effective tools 
for their intended tasks. It should support clinicians’ informed decision making, whether 
they are implementing predictive tools at their clinical practices or recommending such 
tools in clinical practice guidelines to be used by other clinicians. 
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Methods 
  
Guided by the work of Friedman and Wyatt, and their suggested three phases 
approach, which became an internationally acknowledged standard for evaluating health 
informatics technologies [19, 20, 40, 68], we aimed to extract the main criteria along 
which predictive tools can be similarly evaluated before, during and after their 
implementation. 
 
We started with a focused review of the literature in order to examine and collect 
the evaluation criteria, and measures proposed for the appraisal of predictive tools along 
these three phases. The concepts used in the search included “clinical prediction”, 
“tools”, “rules”, “models”, “algorithms”, “evaluation”, and “methods”. The search was 
conducted using four databases; MEDLINE, EMBASE, CINAHL and Google Scholar, with no 
specific timeframe. This literature review was then extended to include studies describing 
methods evaluating CDS systems and more generally, health information systems and 
technology. Following the general concepts of the PRISMA guilines [69], the duplicates of 
the retrieved studies, from the four databases, were first removed. Studies were then 
screened, based on their titles and abstracts, for relevance, then the full text articles were 
assessed for eligibility and only the eligible studies were included in the review. We 
included three types of studies evaluating predictive tools and other CDS systems; 1) 
studies describing the methods or processes of the evaluation, 2) studies describing the 
phases of the evaluation, and 3) studies describing the criteria and measures used in the 
evaluation. The first author manually extracted the methods of evaluation described in 
each type of study, and this was then revised and confirmed by the second and last 
authors. Figure 3, in the Appendix, shows the process of study selection for inclusion in 
the focused review of the literature. 
 
Using the extracted information, we designed an initial version of the framework 
and applied it to asses and grade five predictive tools. We reviewed the complete list of 
426 tools published by the MDCalc medical reference website for decision support tools 
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and applications and calculators (https://www.mdcalc.com) [70]. We excluded tools 
which are not clinical - their output is not related to providing individual patient care, 
such as scores of ED crowding and calculators of waiting times. We also excluded tools 
which are not predictive - their output is not the result of statistically generating new 
information but rather the result of a deterministic equation, such as calculators deriving 
a number from laboratory results. The five example tools were then randomly selected, 
using a random number generator [71], from a shorter list of 107 eligible predictive tools, 
after being alphabetically sorted and numbered. 
 
A comprehensive and systematic search for the published evidence, on each of the 
five predictive tools, was conducted, using MEDLINE, EMBASE, CINAHL and Google 
Scholar, and refined in four steps. 1) The primary studies, describing the development of 
the tools, were first identified and retrieved. 2) All secondary studies that cited the 
primary studies or that referred to the tools’ names or to any of their authors, anywhere 
in the text, were retrieved. 3) All tertiary studies that cited the secondary studies or that 
were used as references by the secondary studies were retrieved. 4) Secondary and 
tertiary studies were examined to exclude non-relevant studies or those not reporting the 
validation, implementation or evaluation of the tools. After the four steps, eligible 
evidence was examined and grades were assigned to the predictive tools. Basic 
information about the tool, such as year of publication, intended use, target population, 
target outcome, and source and type of input data were extracted, from the primary 
studies, to inform the first “Tool Information” section of the framework. Eligible studies 
were then examined in detail for the reported evaluations of the predictive tools. Figure 
4, in the Appendix, shows the process of searching the literature for the published 
evidence on the predictive tools. 
 
The framework and its application to the selected five predictive tools were then 
peer reviewed by six expert healthcare professionals. Three of these professionals are 
clinicians, who work in hospitals and have over ten years of experience using CDS 
systems, while the other three are healthcare researchers, who work in research 
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organisations and have over twenty years of experience in developing, implementing or 
evaluating CDS systems. The reviewers were provided with the framework’s concept 
design and its detailed report template. They were also provided with the summarised 
and detailed grading of the five predictive tools, as well as the justification and published 
evidence underpinning the grade assignment. After a brief orientation session, reviewers 
were asked to feedback on how much they agreed with each of the framework’s 
dimensions and corresponding evaluation criteria, the ‘Tool information’ section as well 
as the grading of the five exemplar predictive tools. The framework was then refined and 
the grading of the five predictive tools was updated based on the reviewers’ feedback. 
Figure 1 shows the flowchart of the GRASP framework overall development process. 
 
Basic Concepts of 
Evaluating Health 
Informatics 
Technologies 
Guided by 
Friedman & Wyatt
Applying GRASP to Grade 
5 Randomly Selected 
Predictive Tools
Focused Review of 
the Literature
Designing the Initial 
GRASP Framework
Peer Review 
Process
Updating the Grading of 
the 5 Predictive Tools
Updating the GRASP 
Framework
Procedures Outcomes
 
Figure 1: The GRASP Framework Development Process 
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Results 
 
The Focused Review of Literature 
 
The search in the four databases, after removing the duplicates, identified a total 
of 831 studies. After screening the titles and abtracts, 647 studies were found not relevant 
to the topic. The full text of the remaining 184 studies were then examined to exclude 
non-eligible studies, which were 134 studies, based on the inclusion criteria. Only fifty 
studies were identified as eligible. Twenty three of the fifty studies described methods 
for the evaluation of predictive tools [10, 12, 23, 39, 43, 45-60, 62, 72], ten studies 
described the evaluation of CDS systems [2, 73-81], and eleven studies described the 
evaluation of hospital information systems and technology [1, 82-91]. One study 
described the NASSS framework, a guideline to help predict and evaluate the success of 
healthcare technologies [92]; and five studies described the GRADE framework for 
evaluating clinical guidelines and protocols [63-67]. The following three subsections 
describe the methods used to evaluate predictive tools as described in the focussed 
literature review. A summary of the evaluation criteria and examples of corresponding 
measures for each phase can be found in Table 3 in the Appendix. 
 
Before Implementation – Predictive performance 
 
During the development phase, the internal validation of the predictive 
performance of a tool is the first step to make sure that the tool is doing what it is 
intended to do [53, 54]. Predictive performance is defined as the ability of the tool to 
utilise clinical and other relevant patient variables to produce an outcome that can be 
used to supports diagnostic, prognostic or therapeutic decisions made by clinicians and 
other healthcare professionals [9, 10]. The predictive performance of a tool is evaluated 
using measures of discrimination and calibration [52]. Discrimination refers to the ability 
of the tool to distinguish between patients with and without the outcome under 
consideration. This can be quantified with measures such as sensitivity, specificity, and 
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the area under the receiver operating characteristic curve – AUC (or concordance statistic, 
c). The D-statistic is a measure of discrimination for time-to-event outcomes, which is 
commonly used in validating the predictive performance of prognostic models using 
survival data [93]. The log-rank test, or sometimes referred to as the Mantel-Cox test, is 
used to establish if the survival distributions of two samples of patients are statistically 
different. They are commonly used to validate the discrimination power of clinical 
prognostic models [94]. On the other hand, calibration refers to the accuracy of 
prediction, and indicates the extent to which expected and observed outcomes agree [47, 
55]. Calibration is measured by plotting the observed outcome rates against their 
corresponding predicted probabilities. This is usually presented graphically with a 
calibration plot that shows a calibration line, which can be described with a slope and an 
intercept [95]. It is sometimes summarised using the Hosmer-Lemeshow test or the Brier 
score [96]. To avoid over-fitting, tools’ predictive performance must always be assessed 
out-of-sample, either via cross-validation or bootstrapping [55]. Of more interest than the 
internal validity is the external validity (reliability or generalisability), where the 
predictive performance of a tool is estimated in independent validation samples of 
patients from different populations [51]. 
 
During Implementation – Potential Effect & Usability 
 
Before wide implementation, it is important to learn about the estimated potential 
effect of a predictive tool, when used in the clinical practice, on three main categories of 
measures: 1) Clinical effectiveness, such as improving patient outcomes, estimated 
through clinical effectiveness studies, 2) Healthcare efficiency, including saving costs and 
resources, estimated through feasibility and cost-effectiveness studies, and 3) Patient 
safety, including minimising complications, side effects, and medical errors. These 
categories are defined by the Institute of Medicine as objectives for improving healthcare 
performance and outcomes, and are differently prioritised by clinicians, healthcare 
professionals and health administrators [97, 98]. The potential effect, of a predictive tool, 
is defined as the expected, estimated or calculated impact of using the tool on different 
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healthcare aspects, processes or outcomes, assuming the tool has been successfully 
implemented and is used in the clinical practice, as designed by its developers [40, 99]. 
A few predictive tools have been studied for their potential to enhance clinical 
effectiveness and improve patient outcomes. For example, the spinal manipulation 
clinical prediction rule was tested, before implementation, on a small sample of patients 
to identify those with low back pain most likely to benefit from spinal manipulation [100]. 
Other tools have been studied for their potential to improve healthcare efficiency and 
save costs. For example, using a decision analysis model, and assuming all eligible 
children with minor blunt head trauma were managed using the CHALICE rule (Children's 
Head Injury Algorithm for the Prediction of Important Clinical Events), it was estimated 
that CHALICE would reduce unnecessary expensive head computed tomography (CT) 
scans, by 20%, without risking patients’ health [101-103]. Similarly, the use of the PECARN 
(Paediatric Emergency Care Applied Research Network) head injury rule was estimated to 
potentially improve patient safety through minimising the exposure of children to 
ionising radiation resulting in fewer radiation-induced cancers and lower net quality 
adjusted life years loss [104, 105]. 
 
In addition, it is important to learn about the usability of predictive tools. Usability 
is defined as the extent to which a system can be used by the specified users to achieve 
specified and quantifiable objectives in a specified context of use [106, 107]. There are 
several methods to make a system more usable and many definitions have been 
developed, based on the perspective of what usability is and how it can be evaluated, 
such as the mental effort needed and the user attitude or the user interaction, represented 
in the easiness of use and acceptability of systems [108, 109]. Usability can be evaluated 
through measuring the effectiveness of task management with accuracy and 
completeness, measuring efficiency of utilising resources in completing tasks and 
measuring users’ satisfaction, comfort with, and positive attitudes towards, the use of 
the tools [110, 111]. More advanced techniques, such as think aloud protocols and near 
live simulations, are recently used to evaluate usability [112]. Think aloud protocols are 
a major method in usability testing, since they produce a larger set of information and a 
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richer content. They are conducted either retrospectively or concurrently, where each 
method has its own way of detecting usability problems [113]. The near live simulations 
provide users, during testing, with an opportunity to go through different clinical 
scenarios while the system captures interaction challenges and usability problems [114, 
115]. Some researchers add learnability, memorability and freedom of errors to the 
measures of usability. Learnability is an important aspect of usability and a major concern 
in the design of complex sysems. It is the capability of a system to enable the users to 
learn how to use it. Momerability, on the other hand, is the capability of a system to 
enable the users to remember how to use it, when they return back. Learnability and 
memorability are measured through subjective survey methods, asking users about their 
experience after using systems, and can also be measured by monitoring users’ 
competence and learning curves over successive sessions of system usage [116, 117]. 
 
After Implementation – Post-Implementation Impact 
 
Some predictive tools have been implemented and used in the clinical practice for 
years, such as the PECARN head injury rule or the Ottawa knee and ankle rules [118-120]. 
In such cases, clinicians might be interested to learn about their post-implementation 
impact. The post-implementation impact of predictive tools is defined as the achieved 
change or influence, of a predictive tool, on different healthcare aspects, processes or 
outcomes, after the tool has been successfully implemented and used in the clinical 
practice, as designed by its developers [2, 41]. Similar to the measures of potential effect, 
post-implementation impact is reported along three main categories of measures: 1) 
Clinical effectiveness, such as improving patient outcomes, 2) Healthcare efficiency, such 
as saving costs and resources, and 3) Patient safety, such as minimising complications, 
side effects, and medical errors. These three categories of post-implementation impact 
measures are differently prioritised by clinicians, healthcare professionals and health 
administrators. In this phase of evaluation, we follow the main concepts of the GRADE 
framework, where the level of evidence for a given outcome is firstly determined by the 
study design [63, 64, 67]. High quality experimental studies, such as randomised and 
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nonrandomised controlled trials, and the systematic reviews of their findings, come on 
top of the evidence levels followed by observational well-designed cohort or case-control 
studies and lastly subjective studies, opinions of respected authorities, and reported of 
expert committees or panels [64-66]. For simplicity, we did not include GRADE’s detailed 
criteria for higher and lower quality of studies. However, effect sizes and potential biases 
are reported as part of the framework, so that consistency of findings, trade-offs between 
benefits and harms, and other considerations can also be assessed. 
 
Developing the GRASP Framework 
 
Our suggested GRASP framework (abbreviated from Grading and Assessment of 
Predictive Tools) is illustrated in Table 1. Based on published evidence, the GRASP 
framework uses three dimensions to grade predictive tools: Phase of Evaluation, Level 
of Evidence and Direction of Evidence.  
 
Phase of Evaluation: Assigns A, B and/or C based on the highest phase of 
evaluation. If a tool’s predictive performance, as reported in the literature, has been 
tested for validity, it is assigned phase C. If a tool’s usability and/or potential effect have 
been tested, it is assigned phase B. Finally, if a tool has been implemented in clinical 
practice, and there is published evidence evaluating its post-implementation impact, it is 
assigned phase A. 
  
Level of Evidence: A numerical score, within each phase, is given based on the 
level of evidence associated with each tool. A tool is graded C1 if it has been tested for 
external validity multiple times; C2 if it has been tested for external validity only once; 
and C3 if it has been only tested for internal validity. Corresponding measures of 
discrimination and calibration, as reported in the literature, are listed; together with 
additional relevant information such as if the study evaluated the tool in a subpopulation 
of the tool’s intended target population. Similarly, B1 is assigned to a predictive tool that 
has been evaluated during implementation for its usability; while if it has been studied 
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for its potential effect on clinical effectiveness, patient safety or healthcare efficiency, it 
is assigned B2. Finally, if a predictive tool had been implemented then evaluated after 
implementation for its post-implementation impact, it is assigned score A1 if there is at 
least one experimental study evaluating its post-implementation impact, A2 if there are 
observational studies evaluating its post-implementation impact and A3 if the post-
implementation impact has been evaluated only through subjective or descriptive 
studies. Effect sizes for each outcome of interest together with study type, clinical 
settings and patient subpopulations are reported. 
 
Direction of Evidence: Due to the large heterogeneity in study design, outcome 
measures and patient subpopulations contained in the studies, synthesising measures of 
predictive performance, usability, potential effect or post-implementation impact into 
one quantitative value is not possible. Furthermore, acceptable values of predictive 
performance or post-implementation impact measures depend on the clinical context and 
the task at hand. For example, tools like Ottawa knee rule [120] and Wells’ criteria [121, 
122] are considered effective only when their sensitivity is very close to 100%, since their 
task is to identify patients with fractures or pulmonary embolism before sending them 
home. On the other hand, tools like LACE Index [123] and Centor score [124] are accepted 
to show sensitivities of around 70%, since their tasks, to predict 30 days readmission risk 
or identify that pharyngitis is bacterial, aim to screen patients who may benefit from 
further interventions. Therefore, for each phase and level of evidence, we assign a 
direction of evidence, based on the conclusions reported in the studies, and provide the 
user with the option to look at the summary of the findings for further information. The 
evidence is considered positive if all studies about a predictive tool reported positive 
conclusions and negative if all studies reported negative or equivocal conclusions. The 
evidence is considered mixed if some studies reported positive and some reported either 
negative or equivocal conclusions. Evaluating the evidence direction based on the 
conclusions of studies is shown in detail in Table 4 in the Appendix. 
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To decide an overall direction of evidence, we developed a protocol to sort the 
mixed evidence into 1) Mixed evidence that supports an overall positive conclusion or 2) 
Mixed evidence that supports an overall negative conclusion. This protocol is based on 
two main criteria; 1) Degree of matching between the evaluation study conditions and the 
original tool specifications, and 2) Quality of the evaluation study. Studies evaluating 
predictive tools in closely matching conditions to the tool specifications and providing 
high quality evidence are considered first; taking into account their conclusions in 
deciding the overall direction of evidence. The mixed evidence protocol is detailed and 
illustrated in Figure 5 in the Appendix. 
 
The final grade of a predictive tool is based on the highest phase of evaluation, 
supported by the highest level of positive evidence, or mixed evidence that supports an 
overall positive conclusion. Figure 2 shows the GRASP framework concept; a visual 
presentation of the framework three dimensions, phase of evaluation, level of evidence, 
and direction of evidence, explaining how each tool is assigned the final grade. Table 1 
shows the GRASP framework detailed report. 
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The predictive tool has been tested for internal validity
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A2
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GRASP Framework – Grading and 
Assessment of Predictive Tools 
for Clinical Decision Support
Healthcare Efficiency
Direction of 
Evidence
Positive
Negative
Mixed supporting 
positive conclusion
Mixed supporting 
negative conclusion
Phase of Evaluation
Level of 
Evidence
 
Figure 2: The GRASP Framework Concept 
 
Table 1: The GRASP Framework Detailed Report 
Name Name of predictive tool (report tool’s creators and year in the absence of a given name) 
Authors/Year Name of developer, country and year of publication 
Intended use Specific aim/intended use of the predictive tool 
Intended user Type of practitioner intended to use the tool  
Category Diagnostic/Therapeutic/Prognostic/Preventive 
Clinical area Clinical specialty 
Target Population Target patient population and health care settings in which the tool is applied 
Target Outcome Event to be predicted (including prediction lead time if needed) 
Action Recommended action based on tool’s output 
Input source 
• Clinical (including Diagnostic, Genetic, Vital signs, Pathology) 
• Non-Clinical (including Healthcare Utilisation) 
Input type 
• Objective (Measured input; from electronic systems or clinical examination) 
• Subjective (Patient reported; history, checklist …etc.) 
Local context Is the tool developed using location-specific data? (e.g. life expectancy tables) 
Methodology Type of algorithm (e.g. parametric/non-parametric) 
Endorsement Organisations endorsing the tool and/or guidelines recommending its utilisation 
Automation Flag Automation status (manual/automated) 
Tool Citations Total citations of the tool Number of studies reporting the tool 
Phase of Evaluation Level of Evidence Grade Evaluation Studies 
Phase C: 
 
Insufficient 
internal validation 
C0 
Tested for internally validity but was either insufficiently 
internally validated or validation was insufficiently reported. 
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Before 
implementation 
 
Is it possible? 
Internal validation C3 
Tested for internally validity (reported calibration & 
discrimination; sensitivity, specificity, positive and negative 
predictive values & other predictive performance measures). 
External validation C2 Tested for external validity, using one external dataset. 
External validation 
multiple times 
C1 
Tested multiple times for external validity, using more than one 
external dataset. 
Phase B:  
 
During 
implementation  
 
Is it practicable? 
Potential effect B2 
Reported estimated potential effect on clinical effectiveness, 
patient safety or healthcare efficiency. 
Usability B1 
Reported usability testing (effectiveness, efficiency, 
satisfaction, learnability, memorability, and minimizing errors). 
Phase A: 
 
After 
implementation: 
  
Is it desirable? 
Evaluation of Post-
Implementation 
Impact on Clinical 
Effectiveness, 
Patient Safety or 
Healthcare 
Efficiency 
A3 
Based on subjective studies; e.g. the opinion of a respected 
authority, clinical experience, a descriptive study, or a report of 
an expert committee or panel. 
A2 
Based on observational studies; e.g. a well-designed cohort or 
case-control study. 
A1 
Based on experimental studies; e.g. a well-designed, widely 
applied randomised/nonrandomised controlled trial. 
Final Grade Grade ABC,123 A1 A2 A3 B1 B2 C1 C2 C3 
Direction of 
Evidence 
 Positive Evidence  Mixed Evidence Supporting Positive Conclusion 
 Negative Evidence  Mixed Evidence Supporting Negative Conclusion 
Justification 
Explains how the final grade is assigned based on evidence; which conclusions were taken into 
consideration, as positive evidence, and which were considered negative. 
References 
Details of studies that support the justification: phase of evaluation, level 
of evidence, direction of evidence, study type, study settings, 
methodology, results, findings and conclusions (highlighted according to 
the colour code). 
These two sections 
are included in the 
full GRASP report on 
each tool. 
Label/Colour Code 
• Positive Findings  
• Negative Findings 
• Important Findings  
• Less Relevant Findings 
 
Applying the GRASP Framework to Grade Five Predictive Tools 
 
In order to show how GRASP works, we applied it to grade five randomly selected 
predictive tools; LACE Index for Readmission [123], Centor Score for Streptococcal 
Pharyngitis [124], Wells’ Criteria for Pulmonary Embolism [121, 122, 125], The Modified 
Early Warning Score (MEWS) for Clinical Deterioration [126] and Ottawa Knee Rule [120]. 
In addition to these seven primary studies, describing the development of the five 
predictive tools, our systematic search for the published evidence revealed a total of fifty 
six studies; validating, implementing, and evaluating the five predictive tools. The LACE 
Index was evaluated and reported in six studies, the Centor Score in fourteen studies, the 
Wells’ Criteria in ten studies, the MEWS in twelve studies, and the Ottawa Knee Rule in 
fourteen studies. To apply the GRASP framework and assign a grade to each predictive 
tool, the following steps were conducted; 1) The primary study or studies were first 
examined for the basic information about the tool and the reported details of 
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development and validation. 2) Other studies were examined for their phases of 
evaluation, levels of evidence and direction of evidence. 3) Mixed evidence was sorted 
into positive or negative. 4) The final grade was assigned and supported by the detailed 
justification. A summary of grading the five tools is shown in Table 2 and a detailed 
GRASP report on each tool is provided in the Appendix; Tables 5 to 9. 
 
LACE Index is a prognostic tool designed to predict 30 days readmission or death 
of patients after discharge from hospitals. It uses multivariable logistic regression 
analysis of four administrative data elements; length of stay, admission acuity, 
comorbidity (Charlson Comorbidity Index) and emergency department (ED) visits in the 
last six months, to produce a risk score [123]. The tool has been tested for external 
validity twice; using a sample of 26,045 patients from six hospitals in Toronto and a 
sample of 59,652 patients from all hospitals in Alberta, Canada. In both studies, the LACE 
Index showed positive external validity and superior predictive performance to the 
previous similar tools endorsed by the Centres for Medicare and Medicaid Services in the 
United States [127, 128]. 
 
Two studies examined the predictive performance of LACE Index on small sub-
population samples; 507 geriatric patients in the United Kingdom and 253 congestive 
heart failure patients in the United States, and found that the index performed poorly 
[129, 130]. Two more studies reported that the LACE Index performed well but not better 
that their own developed tools [131, 132]. Using the mixed evidence protocol, the mixed 
evidence here supports external validity, since the two negative conclusion studies have 
been conducted on very small samples of patients and on different subpopulations than 
the one the LACE Index was developed for. There was no published evidence on the 
usability, potential effect or post-implementation impact of the LACE Index. Accordingly, 
the LACE Index has been assigned Grade C1. 
 
Centor Score is a diagnostic tool that uses a rule-based algorithm on clinical data 
to estimate the probability that pharyngitis is streptococcal in adults who present to the 
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ED complaining of sore throat [124]. The score has been tested for external validity 
multiple times and all the studies reported positive conclusions [133-140]. This qualifies 
Centor score for Grade C1. One study conducted a multicentre cluster RCT usability 
testing of the integration of Centor score into electronic health records. The study used 
“Think Aloud” testing with ten primary care providers, post interaction surveys in 
addition to screen captures and audio recordings to evaluate usability. Within the same 
study, another “Near Live” testing, with eight primary care providers, was conducted. 
Conclusions reported positive usability of the tool and positive feedback of users on the 
easiness of use and usefulness [141]. This qualifies Centor score for Grade B1.  
 
Evidence of the post-implementation impact of Centor score is mixed. One RCT 
conducted in Canada reported a clinically important 22% reduction in overall antibiotic 
prescribing [142]. Four other studies, three of which were RCTs, reported that 
implementing Centor score did not reduce antibiotic prescribing in clinical practice [143-
146]. Using the mixed evidence protocol, we found that the mixed evidence does not 
support positive post-implementation impact of Centor score. Therefore, Centor score 
has been assigned Grade of B1. 
 
Wells’ Criteria is a diagnostic tool used in the ED to estimate pre-test probability 
of pulmonary embolism [121, 122]. Using a rule-based algorithm on clinical data, the tool 
calculates a score that excludes pulmonary embolism without diagnostic imaging [125]. 
The tool was tested for external validity multiple times [147-151] and its predictive 
performance has been also compared to other predictive tools [152-154]. In all studies, 
Wells’ criteria was reported externally valid, which qualifies it for Grade C1. One study 
conducted usability testing for the integration of the tool into the electronic health record 
system of a tertiary care centre’s ED. The study identified a strong desire for the tool and 
received positive feedback on the usefulness of the tool itself. Subjects responded that 
they felt the tool was helpful, organized, and did not compromise clinical judgment [155]. 
This qualifies Wells’ criteria for Grade B1. The post-implementation impact of Well’s 
Criteria on efficiency of computed tomography pulmonary angiography (CTPA) utilisation 
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has been evaluated through an observational before-and-after intervention study. It was 
found that the Well’s Criteria significantly increased the efficiency of CTPA utilisation 
and decreased the proportion of inappropriate scans [156]. Therefore, Well’s Criteria has 
been assigned Grade A2. 
 
The Modified Early Warning Score (MEWS) is a prognostic tool for early detection 
of inpatients’ clinical deterioration and potential need for higher levels of care. The tool 
uses a rule-based algorithm on clinical data to calculate a risk score [126]. The MEWS has 
been tested for external validity multiple times in different clinical areas, settings and 
populations [157-163]. All studies reported that the tool is externally valid. However, one 
study reported MEWS poorly predicted the in-hospital mortality risk of patients with 
sepsis [164]. Using the mixed evidence protocol, the mixed evidence supports external 
validity, qualifying MEWS for Grade C1. No literature has been found regarding its 
usability or potential effect.  
 
The MEWS has been implemented in different healthcare settings. One 
observational before-and-after intervention study failed to prove positive post-
implementation impact of the MEWS on patient safety in acute medical admissions [165]. 
However, three more recent observational before-and-after intervention studies reported 
positive post-implementation impact of the MEWS on patient safety. One study reported 
significant increase in frequency of patient observation and decrease in serious adverse 
events after intensive care unit (ICU) discharge [166]. The second reported significant 
increase in frequency of vital signs recording, 24h post-ICU discharge and 24h preceding 
unplanned ICU admission [167]. The third, an eight years study, reported that the post-
implementation four years showed significant reductions in the incidence of cardiac 
arrests, the proportion of patients admitted to ICU and their in-hospital mortality [168]. 
Using the mixed evidence protocol, the mixed evidence supports positive post-
implementation impact. The MEWS has been assigned Grade A2. 
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Ottawa Knee Rule is a diagnostic tool used to exclude the need for an X-ray for 
possible bone fracture in patients presenting to the ED, using a simple five items manual 
check list [120]. It is one of the oldest, most accepted and successfully used rules in CDS. 
The tool has been tested for external validity multiple times. One systematic review 
identified 11 studies, 6 of them involved 4,249 adult patients and were appropriate for 
pooled analysis, showing high sensitivity and specificity predictive performance [169]. 
Furthermore, two studies discussed the post-implementation impact of Ottawa knee rule 
on healthcare efficiency. One nonrandomised controlled trial with before-after and 
concurrent controls included a total of 3,907 patients seen during two 12-month periods 
before and after the intervention. The study reported that the rule decreased the use of 
knee radiography without patient dissatisfaction or missed fractures and was associated 
with reduced waiting times and costs per patient [170]. Another nonrandomised 
controlled trial reported that the proportion of ED patients referred for knee radiography 
was reduced. The study also reported that the practice based on the rule was associated 
with significant cost savings [171]. Accordingly, the Ottawa knee rule has been assigned 
Grade A1. 
 
In the Appendix, a summary of the predictive performance of the five tools is 
shown in Table 10. The c-statistics of LACE Index, Centor Score, Wells’ Criteria and MEWS 
are reported in Figure 6. The usability of Centor Score and Wells Criteria are reported in 
Table 11 and post-implementation impact of Wells Criteria, MEWS and Ottawa knee rule 
is reported in Table 12.  
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Table 2: Summary of Grading the Five Predictive Tools 
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A1 A2 A3 B1 B2 C1 C2 C3 
LACE Index [123] Canada 2010 455 7 C1      
 
 
 
Centor Score [124] USA 1981 715 15 B1         
Wells’ Criteria [121, 
122, 125] 
Canada 1998 1,260 13 A2         
Modified Early 
Warning Score [126] 
UK 2001 1,176 13 A2         
Ottawa Knee Rule 
[120] 
Canada 1995 227 15 A1         
Evidence Direction 
 Positive Evidence  Mixed Evidence Supporting Positive Conclusion 
 Negative Evidence  Mixed Evidence Supporting Negative Conclusion 
 
Peer Review of the GRASP Framework 
 
On peer-review, experts found the GRASP framework logical, helpful and easy to 
use. The reviewers strongly agreed to all criteria used for evaluation. The reviewers 
suggested adding more specific information about each tool, such as the author’s name, 
the intended user of the tool and the recommended action based on the tool’s findings. 
The reviewers showed a clear demand for knowledge regarding the applicability of tools 
to their local context. Two aspects were identified and discussed with the reviewers. 
Firstly, the operational aspect of how easy it would be to implement a particular tool and 
if the data required to use the tool is readily available in their clinical setting. Secondly, 
the validation aspect of adopting a tool developed using local predictors, such as life 
expectancy (which is location specific) or information based on billing codes (which is 
hospital specific). Following this discussion, elements related to data sources and context 
were added to the information section of the framework. One reviewer suggested 
assigning grade C0 to the reported predictive tools that did not meet C3 criteria, i.e. those 
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tools which were tested for internally validity but were either insufficiently internally 
validated or the internal validation was insufficiently reported in the study, in order to 
differentiate them from those tools for which neither predictive performance nor post-
implementation impact have been reported in the literature. 
 
Discussion and Conclusion 
 
Brief Summary 
 
It is challenging for clinicians to critically evaluate the growing number of 
predictive tools proposed to them by colleagues, administrators and commercial entities. 
Although most of these tools have been assessed for predictive performance, only a few 
have been implemented or evaluated for comparative predictive performance or post-
implementation impact. In this manuscript, we present GRASP, a framework that provides 
clinicians with an objective, evidence-based, standardised method to use in their search 
for, and selection of tools. GRASP builds on widely accepted concepts, such as Friedman 
and Wyatt’s evaluation approach [19, 20, 40, 68] and the GRADE system [63-67]. 
 
The GRASP framework is designed for two levels of users: 1) Expert users, who will 
use the framework to assign grades to predictive tools and report their details, through 
the critical appraisal of published evidence about these tools. Expert users include 
healthcare researchers who specialise in evidence-based methods and have experience in 
developing, implementing or evaluating predictive tools. 2) End users, who will use the 
GRASP framework detailed report of tools and their final grades, produced by expert 
users, to compare existing predictive tools and chose the most suitable for their tasks 
and settings. End users include clinicians and other healthcare professionals involved in 
the decision making and the selection of predictive tools for implementation at their 
clinical practice or for recommendation in clinical practice guidelines to be used by other 
clinicians and healthcare professionals. 
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Comparison with Previous Literature 
 
Previous approaches to the appraisal of predictive tools from the published 
literature, namely the TRIPOD statement [60, 61] and the CHARMS checklist [62], examine 
only their predictive performance, ignoring their usability and post-implementation 
impact. On the other hand, the GRADE framework appraises the published literature in 
order to evaluate clinical recommendations based on their post-implementation impact 
[63-67]. More broadly, methods for the evaluation of health information systems and 
technology focus on the integration of systems into tasks, workflows and organisations 
[83, 89]. The GRASP framework takes into account all phases of the development and 
translation of a predictive algorithm: predictive performance before implementation, 
using similar concepts as those utilised in TRIPOD and CHARMS; usability and potential 
effect during implementation, and post-implementation impact on patient outcomes and 
processes of care after implementation, using similar concepts as those utilised in the 
GRADE system. The GRASP grade is not the result of combining and synthesising selected 
measures of predictive performance (e.g. AUC), potential effect (e.g. potential saved 
money), usability (e.g. user satisfaction) or post-implementation impact (e.g. increased 
efficacy) from the existing literature, like in a meta-analysis; but rather the result of 
combining and synthesising the reported qualitative conclusions.  
 
Walker and Habboushe, at the MDCalc website; classified and reported the most 
commonly used medical calculators and other clinical decision support applications. 
However, the website does not provide users with a structured grading system or an 
evidence-based method for the assessment of the presented tools. Therefore, we believe 
that our proposed framework can be adopted and used by MDCalc, and similar clinical 
decision support resources, to grade their tools. 
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Quality of Evidence and Conflicting Conclusions 
 
One of the main challenges is dealing with the large variability in the quality and 
type of studies in the published literature. This heterogeneity makes it impractical to 
synthesise measures of predictive performance, usability, potential effect or post-
implementation impact into single numbers. Furthermore, as discussed earlier, a 
particular value of a predictive performance metric that is considered good for some tasks 
and clinical settings may be considered insufficient for others. In order to avoid complex 
decisions regarding the quality and strength of reported measures, we chose to assign a 
direction of evidence, based on positive or negative conclusions as reported in the studies 
under consideration. We then provide the end user with the option to look at a summary 
of reported measures for further details. 
 
It is not uncommon to encounter conflicting conclusions when a tool has been 
validated in different patient subpopulations. For example, LACE Index for readmission 
showed positive external validity when tested in adult medical inpatients [127, 128], but 
showed poor predictive performance when tested in a geriatric subpopulation [129]. 
Similarly, the MEWS for clinical deterioration demonstrated positive external validity 
when tested in emergency patients [157, 159, 163], medical inpatients [158, 162], surgical 
inpatients [160], and trauma patients [161], but not when tested in a subpopulation of 
patients with acute sepsis [164]. Part of these disagreements could be explained by 
changes in the distributions of important predictors, which affect the discriminatory 
power of the algorithms. For example, sepsis patients have similarly disturbed 
physiological measures such as those used to generate MEWS. In addition, conflicting 
conclusions may be encountered when a study examines the validity of a proposed tool 
in a healthcare setting or outcome different from those the tool was primarily developed 
for.  
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Integration and Socio-Technical Context 
 
As is the case with other healthcare interventions, examining the post-
implementation impact of predictive tools is challenging, since it is confounded by co-
occurrent socio-technical factors [173-175]. This is complicated further by the fact that 
predictive tools are often integrated into electronic health record systems, since this 
facilitates their use, and are influenced by their usability [41, 176]. The usability, 
therefore, is an essential and major contributing factor in the wide acceptance and 
successful implementation of predictive tools and other CDS systems [41, 177]. It is 
clearly essential to involve user clinicians in the design and usability evaluations of 
predictive tools before their implementation. This should eliminate their concerns that 
integrating predictive tools into their workflow would increase their workload, 
consultation times, or decrease their efficiency and productivity [178].  
 
Likewise, well designed post-implementation impact evaluation studies are 
required in order to explore the influence of organisational factors and local differences 
on the success or failure of predictive tools [179, 180]. Data availability, IT systems 
capabilities, and other human knowledge and organisational regulatory factors are crucial 
for the adoption, acceptance, and successful implementation of predictive tools. These 
factors and differences need to be included in the tools assessments, as they are 
important when making decisions about selecting predictive tools, in order to estimate 
the feasibility and resources needed to implement the tools. We have to acknowledge that 
it is not possible to include such wide range of variables in deciding or presenting the 
grades assigned by the framework to the predictive tools, which remain simply at a high-
level. However, all the necessary information, technical specifications, and requirements 
of the tools, as reported in the published evidence, should be fully accessible to the users, 
through the framework detailed reports on the predictive tools. Users can compare such 
information, of one or more tools, to what they have at their healthcare settings, then 
make selection and implementation decisions. 
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Local Data 
 
There is a challenging trade-off between the generalisability and the customisation 
of a given predictive tool. Some algorithms are developed using local data. For example, 
Bouvy's prognostic model, for mortality risk in patients with heart failure, uses life quality 
and expectancy scores from the Netherlands [181]. Similarly, Fine’s prediction rule 
identifies low-risk patients with community-acquired pneumonia based on national rates 
of acquired infections in the United States [182]. This necessitates adjustment of the 
algorithm to the local context, therefore producing a new version of the tool, which 
requires re-evaluation.  
 
Other Considerations 
 
GRASP evaluates predictive tools based on the existing published evidence. 
Therefore, it is subject to publication bias, since statistically positive results are more 
likely to be published than negative or null results [183, 184]. The usability and potential 
effect of predictive tools are less studied and hence the published evidence needed to 
support level B of the grading system is often lacking. We have nevertheless chosen to 
keep this element in GRASP since it is an essential part of the safety evaluation of any 
healthcare technology. It also allows for early redesign and better workflow integration, 
which leads to higher utilisation rates [112, 155, 185]. By keeping it, we hope to encourage 
tool developers and evaluators to increase their execution and reporting of these type of 
studies. 
 
The grade assigned to a tool provides relevant evidence-based information to 
guide choices on predictive tools for clinical decision support, but it is not prescriptive. 
An A1 tool is not always better than an A2 tool. A user may prefer an A2 tool showing 
improved patient safety in two observational studies rather than an A1 tool showing 
reduced cost in one experimental study. The grade is a code (not an ordinal quantity) that 
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provides information on three relevant dimensions: phase of evaluation, level of 
evidence, and direction of evidence as reported in the literature. 
 
Study Limitations and Future Work 
 
We applied the GRASP framework to only five predictive tools and consulted a 
small number of healthcare experts for their feedback. This could have limited the 
conclusions about the framework’s coverage and/or validity. Although GRASP framework 
is not a predictive tool, it could be thought of as a technology of Grade C3, since it has 
only been internally validated after development. However, conducting a large-scale 
validation study of the framework, extending the application of the framework to a larger 
number of predictive tools, and studying its effect on end-users’ decisions is out of the 
scope of this study. To validate, test and improve the GRASP framework, the authors are 
currently working on three more studies. The first study should validate the design and 
content of the framework, through seeking the feedback of a wider international group of 
healthcare experts, who have published work on developing, implementing or evaluating 
predictive tools. This study should help to update the criteria used, by the framework, to 
grade predictive tools and improve the details provided, by the framework, to the end 
users. The second study should validate and evaluate the impact of using the framework 
on improving the decisions made by clinicians, regarding evaluating and choosing 
predictive tools. The experiment should compare the performance and outcomes of 
clinicians’ decisions with and without using the framework. Finally, the third study aims 
to apply the framework to a larger consistent group of predictive tools, used for the same 
clinical task. This study should show how the framework provides clinicians with an 
evidence-based method to compare, evaluate and select predictive tools, through 
reporting and grading tools based on the critical appraisal of published evidence. 
 
Implementing the GRASP framework as an online platform will enable clinicians 
and clinical practice guideline developers to access detailed information, reported 
evidence and grades of predictive tools. However, keeping such grading system up-to-
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date is a challenging task, since it requires updating tools’ assessments and grades when 
new evidence becomes available. Therefore, a sustainable GRASP system will require 
employing automated or semi-automated methods for searching and processing new 
information. Finally, we recommend that GRASP framework be applied to predictive tools 
by working groups of professional organisations, in order to provide consistent results 
and increase reliability and credibility for end users. These professional organisations 
should also be responsible for making their associates aware of the availability of such 
evidence-based information on predictive tools, in a similar way of announcing and 
disseminating clinical practice guidelines. 
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The Appendix 
 
Phases, Criteria, and Measures of Evaluation 
 
Table 3: Phases, Criteria, and Measures of Evaluating Predictive Tools 
Phase of 
Evaluation 
Criteria of 
Evaluation 
Definitions Example Measures* 
Before 
Implementation 
Predictive 
Performance 
The ability of the predictive tool to 
utilise clinical variables and quantify 
relevant patient characteristics to 
produce an outcome that can be used to 
supports diagnostic, prognostic or 
therapeutic decisions made by 
clinicians and other healthcare 
professionals [9, 10]. 
Discrimination:  
• Sensitivity 
• Specificity 
• AUC, ROC, and C-Statistic 
• D-Statistic 
• Log-Rank Test. 
 
Calibration:  
• Calibration Plots & Curves 
• Hosmer-Lemeshow test 
• The Brier score. 
During 
Implementation 
Usability 
The degree to which the predictive tool 
can be used by the specified users to 
achieve specified and quantifiable 
objectives in a specified context of use 
[106, 107]. 
• Effectiveness of task management 
(accuracy and completeness). 
• Efficiency of utilising resources. 
• Users’ satisfaction, comfort with, and 
positive attitudes towards, the use of 
the tools.  
• Learnability 
• Memorability 
• Freedom of Errors. 
Potential Effect 
The expected, estimated or calculated 
impact of using the tool on different 
healthcare aspects, processes or 
outcomes, assuming the tool has been 
successfully implemented and used in 
the clinical practice, as designed by its 
developers [40, 99].  
• Clinical Effectiveness (Clinical Patient 
Outcomes).  
• Patient Safety (Complications, Side 
Effects, or Medical Errors). 
• Healthcare Efficiency (Utilisation of 
Resources, Such as Time and Money). 
After 
Implementation 
Post-
Implementation 
Impact 
The achieved change or influence of a 
predictive tool on different healthcare 
aspects, processes or outcomes, after 
the tool has been successfully 
implemented and used in the clinical 
practice, as designed by its developers 
[2, 41]. 
• Clinical Effectiveness (Clinical Patient 
Outcomes).  
• Patient Safety (Complications, Side 
Effects, or Medical Errors). 
• Healthcare Efficiency (Utilisation of 
Resources, Such as Time and Money). 
 
* These measures of evaluation are examples, the list is not meant to be exhaustive; 
literature on predictive tools may evaluate them along other measures. 
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Evaluating Evidence Direction 
 
Table 4: Evaluating Evidence Direction Based on the Conclusions of Studies 
Conclusions of Studies 
Overall Direction of 
Evidence 
Positive * Equivocal ** Negative *** 
 
  Positive 
 
 
 
Mixed 
   
  
 
  
 
Negative  
  
 
 
 
* Positive Conclusion 
• The tool shows positive valid predictive performance, usability, potential effect, or post-
implementation impact, which are desirable and/or superior to other methods/tools, if 
the study includes a comparison. 
** Equivocal Conclusion 
• The tool shows positive valid predictive performance or usability, which are acceptable, 
but not superior to other methods/tools, if the study includes a comparison. 
• The tool does not show positive potential effect or post-implementation impact. These 
are inferior to other methods/tools, if the study includes a comparison. 
*** Negative Conclusion 
• The tool shows that predictive performance or usability is poor, not acceptable, or 
inferior to other methods/tools, if the study includes a comparison. 
• The tool shows negative potential effect or post-implementation impact (leads to 
deterioration instead of improvement), whether in comparison or not. 
 
GRASP Detailed Reports on Predictive Tools 
 
Table 5: LACE Index for Readmission – Grade C1 
Name LACE Index for Readmission 
Authors/Year Dr. Carl van Walraven, Canada, 2010 
Intended use Predicts 30 days readmission or death risk of medical and surgical inpatients after discharge 
Intended user Used by nurses at patient discharge 
Category Prognostic 
Clinical area All medical/surgical areas 
Target 
Population 
Hospitalised patients 
Target Outcome 30 days readmission or death 
Action Inform the clinical team about patients at high risk for readmission 
Input source 
Objective data (Data is available in the EHR – electronic health record, or manually obtained from the 
patient medical record). 
Input type 
Administrative data: Length of stay (days), Admission acuity (yes/no), Comorbidity (Charlson Index), 
Number of ED visits within 6 months. 
Local context Input does not depend on local context of data 
Methodology Multivariable logistic regression analysis 
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Endorsement 
Recommended by: 
• Texas Healthcare Association, USA. 
• American Heart Association, USA. 
• Michigan Care Management Resource Center, USA 
Automation Flag Manual 
Tool Citations 455 Reported in 7 studies 
Phase of 
Evaluation 
Level of Evidence Grade Evaluation Studies 
Phase C: 
Before 
implementation 
Does the tool 
work? Is it 
possible? 
Internal validation C3 
Developed and tested for internal validity: 
• van Walraven et al, 2010 [123] 
External validation C2 
Tested for externally validity: 
• Gruneir et al, 2011 [128] 
External validation 
multiple times 
C1 
Tested for external validity again:  
• Au et al, 2012 [127] 
Negative conclusion validation/performance studies: 
• Cotter et al, 2012 [129] 
• Wang et al, 2014 [130] 
• Low et al, 2015 [131] 
• Yu et al, 2015 [132] 
Phase B:  
During 
implementation:  
Is the tool 
practicable? 
Potential effect B2 Not reported 
Usability B1 Not reported 
Phase A: 
After 
implementation:  
Is the tool 
desirable? 
Evaluation of Post-
Implementation 
Impact on Clinical 
Effectiveness, 
Patient Safety or 
Healthcare 
Efficiency 
A3 No subjective studies reported 
A2 No observational studies reported 
A1 No experimental studies reported 
Final Grade Grade C1 A1 A2 A3 B1 B2 
 
C2 
 
Direction of 
Evidence 
 Positive Evidence  Mixed Evidence Supporting Positive Conclusion 
 Negative Evidence  Mixed Evidence Supporting Negative Conclusion 
Justification 
LACE Index is a prognostic tool designed to predict 30 days readmission or death after discharge from 
hospital. It uses multivariable logistic regression analysis of administrative data: length of stay, 
admission acuity, comorbidity (Charlson Comorbidity Index) and emergency department (ED) visits 
in the last six months, to produce a risk score [123]. The tool has been tested for external validity 
twice: using a sample of 26,045 patients from six hospitals in Toronto and a sample of 59,652 patients 
from all hospitals in Alberta. The LACE Index showed external validity and superior predictive 
performance to previous tools endorsed by the Centres for Medicare and Medicaid Services [127, 128]. 
Two studies examined LACE Index predictive performance on small sub-population samples: 507 
geriatric patients in the UK, and 253 congestive heart failure patients in the USA, and found that the 
index performed poorly [129, 130]. Two more studies reported that LACE Index works well but their 
own developed tools performed better [131, 132]. Using the mixed evidence protocol, the mixed 
evidence supports external validity, since the two negative conclusion studies have been conducted 
on very small samples of patients and a different subpopulation than the one LACE was developed 
for. There was no published evidence on the usability, potential effect or post-implementation impact 
of LACE Index. Accordingly, LACE Index has been assigned Grade C1. 
 
Table 6: Centor Score for Streptococcal Pharyngitis – Grade B1 
Name Centor Score for Streptococcal Pharyngitis 
Authors/Year Dr. Robert M. Centor, USA, 1981. Modified later by Dr. Warren McIsaac, Canada, 1998. 
Intended use 
Estimate the probability that pharyngitis is streptococcal in adult patients presenting to the 
emergency department with sore throat 
Intended user Used by physicians at ED as part of the clinical examination 
Category Diagnostic 
Clinical area Infectious diseases 
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Target 
Population 
Patients visiting the emergency department 
Target Outcome Streptococcal pharyngitis 
Action Consider rapid strep testing and/or culture 
Input source Objective data (clinical examination) + Subjective data (symptoms described by patient) 
Input type 
Clinical data: Age (3-14, 15-44 & >45 years), Exudate or swelling on tonsils (yes/no), Tender/swollen 
anterior cervical lymph nodes (yes/no), Temp >38°C (100.4°F) (yes/no), Cough (present/absent). Data 
is obtained from the patient. 
Local context Input does not depend on local context of data 
Methodology Rule-based algorithm 
Endorsement 
Recommended by: 
• Department of Health, New South Wales, Australia 
• American Academy of Family Physicians, United States 
• The National Institute for Health and Care Excellence, United Kingdom 
Automation Flag Manual 
Tool Citations 715 Reported in 15 studies 
Phase of 
Evaluation 
Level of Evidence Grade Evaluation Studies 
Phase C: 
Before 
implementation 
Does the tool 
work? Is it 
possible? 
Internal validation C3 
Developed and tested for internal validity: 
• Centor et al, 1981 [124] 
External validation C2 
Tested for external validity: 
• Wigton, Connor & Centor, 1986 [140] 
External validation 
multiple times 
C1 
Tested for external validity multiple times: 
• Poses et al, 1986 [139] 
• Meland, Digranes & Skjærven, 1993 [138] 
• Ebell et al, 2000 [135] 
• McIsaac et al, 2004 [137] 
• Aalbers et al, 2011 [133] 
• Fine, Nizet & Mandl, 2012 [136] 
• Alper et al, 2013 [134] 
Phase B:  
During 
implementation:  
Is the tool 
practicable? 
Potential effect B2 Not reported 
Usability B1 
Reported usability testing is positive: 
• Feldstein et al, 2017 [141] 
Phase A: 
After 
implementation:  
Is the tool 
desirable? 
Evaluation of Post-
Implementation 
Impact on Clinical 
Effectiveness, 
Patient Safety or 
Healthcare 
Efficiency 
A3 No subjective studies reported 
A2 No observational studies reported 
A1 
One RCT show positive post-implementation impact of Centor 
score on reducing unnecessary antibiotics prescribing: 
• McIsaac et al, 1998 [142] 
One observational study + 3 RCTs show negative conclusions 
(No impact of Centor score on antibiotics prescribing): 
• McIsaac et al, 1998 [144] 
• Poses, Cebul & Wigton, 1995 [145] 
• Worrall et al, 2007 [146] 
• Little et al, 2014 [143] 
Final Grade Grade B1 
 
A2 A3 
 
B2 
 
C2 
 
Direction of 
Evidence 
 Positive Evidence  Mixed Evidence Supporting Positive Conclusion 
 Negative Evidence  Mixed Evidence Supporting Negative Conclusion 
Justification 
Centor score is a diagnostic tool that uses a rule-based algorithm on clinical data to estimate the 
probability that pharyngitis is streptococcal in adults who present to ED complaining of sore throat 
[124]. The score has been tested for external validity multiple times and all studies reported positive 
conclusions [133-140]. This qualifies Centor score for Grade C1. One study conducted a multicentre 
cluster RCT usability testing of the integration of Centor score into electronic health records. The 
study used “Think Aloud” testing with ten primary care providers, post interaction surveys in addition 
to screen captures and audio recordings to evaluate usability. Within the same study, another “Near 
Live” testing, with eight primary care providers, was conducted. Conclusions reported positive 
usability of the tool and positive feedback of users on the easiness of use and usefulness [141]. This 
qualifies Centor score for Grade B1. Evidence of the post-implementation impact of Centor score post-
implementation is mixed. One RCT conducted in Canada reported a clinically important 22% reduction 
in overall antibiotic prescribing [142]. Four other studies, three of which were RCTs, reported that 
implementing Centor score did not reduce antibiotic prescribing in clinical practice [143-146]. Using 
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the mixed evidence protocol, the mixed evidence does not support positive post-implementation 
impact of Centor score. Therefore, Centor score has been assigned Grade B1. 
 
Table 7: Wells’ Criteria for Pulmonary Embolism – Grade A2 
Name Wells’ Criteria for Pulmonary Embolism 
Authors/Year Dr. Phil Wells, Canada, 1998. 
Intended use Calculates the pre-test probability (risk)v of pulmonary embolism at the bedside without imaging 
Intended user Used by physicians at ED as part of the clinical examination 
Category Diagnostic 
Clinical area Cardiovascular diseases 
Target 
Population 
Patients visiting the emergency department 
Target Outcome Pulmonary embolism 
Action Rule out high risk patients with computed tomography angiography 
Input source Objective data (clinical examination) + Subjective data (symptoms described by patient). 
Input type 
Clinical data: Clinical signs and symptoms of DVT (yes/no), PE is #1 diagnosis OR equally likely 
(yes/no), Heart rate > 100 (yes/no), Immobilization at least 3 days OR surgery in the previous 4 weeks 
(yes/no), Previous, objectively diagnosed PE or DVT (yes/no), Haemoptysis (yes/no), Malignancy w/ 
treatment within 6 months or palliative (yes/no). 
Local context Input does not depend on local context of data 
Methodology Rule-based algorithm 
Endorsement 
Recommended by: 
• New South Wales Agency for Clinical Innovation, Australia 
• The Royal Australian College of General Practitioners, Australia 
Automation Flag Manual 
Tool Citations 1,260 Reported in 13 studies 
Phase of 
Evaluation 
Level of Evidence Grade Evaluation Studies 
Phase C: 
Before 
implementation 
Does the tool 
work? Is it 
possible? 
Internal validation C3 
Developed and tested for internal validity: 
• Wells et al, 1998 [122] 
• Wells et al, 2000 [121] 
• Wells et al, 2001 [125] 
External validation C2 
Tested for external validity: 
• Page, 2006 [149] 
External validation 
multiple times 
C1 
Tested for external validity multiple times: 
• Gibson et al, 2008 [148] 
• Klok et al, 2008 [153] 
• Söderberg et al, 2009 [151] 
• Geersing et al, 2012 [147] 
• Arslan et al, 2013 [152] 
• Posadas-Martínez et al, 2014 [150] 
• Turan et al, 2017 [154] 
Phase B:  
During 
implementation:  
Is the tool 
practicable? 
Potential effect B2 Not reported 
Usability B1 
Reported usability testing is positive: 
• Press et al, 2015 [155] 
Phase A: 
After 
implementation:  
Is the tool 
desirable? 
Evaluation of Post-
Implementation 
Impact on Clinical 
Effectiveness, 
Patient Safety or 
Healthcare 
Efficiency 
A3 No subjective studies reported 
A2 
Observational before-and-after intervention study showing 
positive post-implementation impact of Wells’ Criteria on 
healthcare efficiency: 
• Murthy et al, 2016 [156] 
A1 No experimental studies reported 
Final Grade Grade A2 A1 
 
A3 
 
B2 
 
C2 
 
 Positive Evidence  Mixed Evidence Supporting Positive Conclusion 
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Direction of 
Evidence 
 Negative Evidence  Mixed Evidence Supporting Negative Conclusion 
Justification 
Wells’ criteria is a diagnostic tool used in ED to estimate pre-test probability of pulmonary embolism 
[121, 122]. Using a rule-based algorithm on clinical data, the tool calculates a score that excludes 
pulmonary embolism without diagnostic imaging [125]. The tool was tested for external validity 
multiple times [147-151] and its predictive performance has been also compared to other predictive 
tools [152-154]. In all studies, Wells’ criteria was reported valid, which qualifies it for Grade C1. One 
study conducted usability testing for the integration of the tool into the electronic health record 
system of a tertiary care centre’s ED. The study identified a strong desire for the tool and received 
positive feedback on the usefulness of the tool itself. Subjects responded that they felt the tool was 
helpful, organized, and did not compromise clinical judgment [155]. This qualifies Wells’ criteria for 
Grade B1. The post-implementation impact of Well’s Criteria on efficiency of computed tomography 
pulmonary angiography (CTPA) utilisation has been evaluated through an observational before-and-
after intervention study. It was found that the Well’s Criteria significantly increased the efficiency of 
CTPA utilisation and decreased the proportion of inappropriate scans [156]. Therefore, Well’s Criteria 
has been assigned Grade A2. 
 
Table 8: Modified Early Warning Score (MEWS) – Grade A2 
Name Modified Early Warning Score (MEWS) for Clinical Deterioration 
Authors/Year Dr. Christian Peter Subbe, UK, 2001 
Intended use 
Early detection of inpatients’ clinical deterioration, calculate chance of ICU admission or death within 
60 days and potential need for higher levels of care. 
Intended user Used by nurses at bedside 
Category Prognostic 
Clinical area General Medicine 
Target 
Population 
Hospitalised patients 
Target Outcome Clinical deterioration/death 
Action Consider higher level of care for patient (e.g. transfer to ICU) 
Input source Objective (Data from EHR – electronic health record) 
Input type Clinical data: Systolic BP, Heart rate, Respiratory rate, Temperature, AVPU Score. 
Local context Input does not depend on local context of data 
Methodology Rule-based algorithm 
Endorsement 
Recommended by: 
• Australian Commission on Safety and Quality in Health Care, Australia  
• National Health Services, United Kingdom 
Automation Flag Automated (However, in some hospitals a manual version is still used by nurses) 
Tool Citations 1,176 Reported in 13 studies 
Phase of 
Evaluation 
Level of Evidence Grade Evaluation Studies 
Phase C: 
Before 
implementation 
Does the tool 
work? Is it 
possible? 
Internal validation C3 
Developed and tested for internal validity: 
• Subbe et al, 2001 [126] 
External validation C2 
Tested for External validity: 
• Armagan et al, 2008 [157] 
External validation 
multiple times 
C1 
Tested for external validity multiple times: 
• Burch, Tarr & Morroni, 2008 [158] 
• Dundar et al, 2016 [159] 
• Gardner-Thorpe et al, 2006 [160] 
• TANRIÖVER et al, 2016 [162] 
• Wang et al, 2016 [163] 
• Salottolo et al, 2017 [161] 
One negative conclusion validation/performance study: 
• Tirotta et al, 2017 [164] 
Phase B:  
During 
implementation:  
Is the tool 
practicable? 
Potential effect B2 Not reported 
Usability B1 Not reported 
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Phase A: 
After 
implementation:  
Is the tool 
desirable? 
Evaluation of Post-
Implementation 
Impact on Clinical 
Effectiveness, 
Patient Safety or 
Healthcare 
Efficiency 
A3 No subjective studies reported 
A2 
One observational before-and-after intervention study failed to 
prove positive post-implementation impact of the MEWS on 
patient safety: 
• Subbe et al, 2003 [165] 
Three observational before-and-after intervention studies 
showed positive post-implementation impact of the MEWS on 
patient safety: 
• Moon et al, 2011 [168] 
• De Meester et al, 2013 [166] 
• Hammond et al, 2013 [167] 
A1 No experimental studies reported 
Tool Grade Grade A2 A1 
 
A3 B1 B2 
 
C2 
 
Direction of 
Evidence 
 Positive Evidence  Mixed Evidence Supporting Positive Conclusion 
 Negative Evidence  Mixed Evidence Supporting Negative Conclusion 
Justification 
The MEWS is a prognostic tool for early detection of inpatients’ clinical deterioration and potential 
need for higher levels of care. The tool uses a rule-based algorithm on clinical data to calculate a risk 
score [126]. The MEWS has been tested for external validity multiple times in different clinical areas, 
settings and populations [157-163]. All studies reported the tool is externally valid. However, one 
study reported MEWS poorly predicted the in-hospital mortality risk of patients with sepsis [164]. 
Using the mixed evidence protocol, the mixed evidence supports external validity, qualifying MEWS 
for Grade C1. No literature has been found regarding its usability or potential effect. The MEWS has 
been implemented in different healthcare settings. One observational before-and-after intervention 
study failed to prove positive post-implementation impact of the MEWS on patient safety in acute 
medical admissions [165]. However, three more recent observational before-and-after intervention 
studies reported positive post-implementation impact of the MEWS on patient safety. One study 
reported significant increase in frequency of patient observation and decrease in serious adverse 
events after intensive care unit (ICU) discharge [166]. The second reported significant increase in 
frequency of vital signs recording, 24h post-ICU discharge and 24h preceding unplanned ICU 
admission [167]. The third, an eight years study, reported that the post-implementation four years 
showed significant reductions in the incidence of cardiac arrests, the proportion of patients admitted 
to ICU and their in-hospital mortality [168]. Using the mixed evidence protocol, the mixed evidence 
supports positive post-implementation impact. The MEWS has been assigned Grade A2. 
 
Table 9: Ottawa Knee Rule – Grade A1 
Name Ottawa Knee Rule 
Authors/Year Dr. Ian Stiell, Canada, 1995 
Intended use Exclude the need for an X-ray for possible bone fracture in adult patients 
Intended user Used by emergency physicians as part of the clinical examination 
Category Diagnostic 
Clinical area Orthopaedics 
Target 
Population 
Patients visiting the emergency department 
Target Outcome Bone fracture 
Action Refer patient to knee imaging 
Input source Objective data (clinical examination) + Subjective data (symptoms described by patient) 
Input type 
Clinical data: Age ≥55 (yes/no), Isolated tenderness of the patella (no other bony tenderness) (yes/no), 
Tenderness at the fibular head (yes/no), Unable to flex knee to 90° (yes/no), Unable to bear weight 
both immediately and in ED (4 steps, limping is okay) (yes/no). Data is obtained from the patient. 
Local context Input does not depend on local context of data 
Methodology Set of rules 
Endorsement 
Recommended by: 
• Department of Emergency Medicine, Faculty of medicine, Ottawa University, Canada 
• The Royal College of Radiologists, United Kingdom 
• The National Institute for Health and Care Excellence, United Kingdom 
Automation Flag Manual 
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Tool Citations 227 Reported in 15 studies 
Phase of 
Evaluation 
Level of Evidence Grade Evaluation Studies 
Phase C: 
Before 
implementation 
Does the tool 
work? Is it 
possible? 
Internal validation C3 
Developed and tested for internal validity: 
• Stiell et al, 1995 [120] 
External validation C2 Tested for externally validity 
External validation 
multiple times 
C1 
Externally tested for externally validity (One systematic review 
reported 11 validation studies): 
• Bachmann et al, 2004 [169] 
Phase B:  
During 
implementation:  
Is the tool 
practicable? 
Potential effect B2 Not reported 
Usability B1 Not reported 
Phase A: 
After 
implementation:  
Is the tool 
desirable? 
Evaluation of Post-
Implementation 
Impact on Clinical 
Effectiveness, 
Patient Safety or 
Healthcare 
Efficiency 
A3 No subjective studies reported 
A2 No observational studies reported 
A1 
Two nonrandomised controlled studies reported positive post-
implementation impact of Ottawa knee rule on healthcare 
efficiency: 
• Stiell et al, 1997 [170] 
• Nichol et al, 1999 [171] 
Final Grade Grade A1 
 
A2 A3 B1 B2 
 
C2 
 
Direction of 
Evidence 
 Positive Evidence  Mixed Evidence Supporting Positive Conclusion 
 Negative Evidence  Mixed Evidence Supporting Negative Conclusion 
Justification 
Ottawa knee rule is a diagnostic tool used to exclude the need for an X-ray for possible bone fracture 
in patients presenting to the ED, using a simple five items manual check list [120]. It is one of the 
oldest, most accepted and successfully used rules in CDS. The tool has been tested for external 
validity multiple times. One systematic review identified 11 studies, 6 of them involved 4,249 adult 
patients and were appropriate for pooled analysis, showing high sensitivity and specificity [169]. 
Furthermore, two studies discussed the impact of implementing Ottawa knee rule on healthcare 
efficiency. One nonrandomised controlled trial with before-after and concurrent controls included a 
total of 3,907 patients seen during two 12-month periods before and after the intervention. The study 
reported that the rule decreased the use of knee radiography without patient dissatisfaction or missed 
fractures and was associated with reduced waiting times and costs per patient [170]. Another 
nonrandomised controlled trial reported that the proportion of ED patients referred for knee 
radiography was reduced. The study also reported that the practice based on the rule was associated 
with significant cost savings [171]. The Ottawa knee rule has been assigned Grade A1. 
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Predictive Performance, Usability and Post-implementation Impact Tables of 
Predictive Tools 
 
Table 10: Predictive Performance of the Five Tools – Before Implementation 
Tool 
Discrimination Calibration  
AUC/C-Statistic Sensitivity, Specificity, Cut-Off 
Hosmer–Lemeshow 
goodness-of-fit 
LACE 
Index 
• 0.68 (95% CI, 0.68–0.69) [123] 
• 0.68 [127] 
• 0.56 (95% CI, 0.46–0.66) [186] 
• 66.3%, 53.3%, 50% [131] • 14.1 (P=0.59) [123] 
Centor 
Score 
• 0.78 [124] 
• 0.72 [136] 
• 0.84 [134] 
• 90%, 92%, 50% [124] 
• 49%, 82%, 50% [133] 
• 92%, 73%, 50% [137] 
• 92%, 63%, 50% [134] 
• Not reported 
Wells' 
Criteria 
• 0.71 [151] 
• 0.75 [152] 
• 0.79 (95% CI, 0.75-0.82) [150] 
• 0.79 (95% CI, 0.72–0.87) [153] 
• 0.76 [154] 
• 0.74 (95% CI,0.72-0.76) [148] 
• 83%, 48%, 50% [151] 
• 65%, 81%, 50% [150] 
• 100%, 56%, 50% [154] 
• 95%, 51%, 50% [147] 
• Not reported 
MEWS 
• 0.73 (95% CI, 0.69–0.77) –
Hospitalisation [159] 
• 0.89 (95% CI 0.84–0.94) – In-
hospital mortality [159] 
• 0.79 (95% CI, 0.74-0.83) – 
Mortality [161] 
• 0.56 (95% CI, 0.51 to 0.62) – ICU 
Admission [161] 
• 0.85 (95% CI, 0.77–0.91) [162] 
• 0.80 (95% CI, 0.72–0.88) [36] 
• 0.76 – Mortality [187] 
• 88%, 68%, 50% (MEWS≥3) [160] 
• 53%, 91%, 50% (MEWS≥4) Mortality 
[161] 
• 17%, 94%, 50% (MEWS≥4) ICU 
Admission [161] 
• 86%, 94%, 50% (MEWS≥4) [162] 
• 75%, 83%, 50% (MEWS≥4) [188] 
• 57%, 86%, 50% (MEWS≥4) [187] 
• P=0.06 [189] 
Ottawa 
Knee Rule 
• Not reported 
• 98.5%, 48.6%, 50% [169]* 
• 100% [170] 
• 100%, 42.8%, 50% [190] 
• 95%, 44%, 50% [191] 
• Not reported 
 
* A systematic review study. 
 
Table 11: Usability of Two Predictive Tools – During Implementation 
Tool Study Type Method Outcomes 
Centor Score Usability testing [141] 
Think Aloud + Near 
Live 
• Positive usability & feedback of users 
o Easiness of use 
o Usefulness 
Wells' Criteria Usability testing [155] 
Think Aloud + Near 
Live 
• Positive usability & feedback of users 
o Tool is helpful 
o Organized 
o Did not compromise clinical judgment 
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Table 12: Post-Implementation Impact of Three Predictive Tools 
Tool Study Type Study Settings Outcome Effect Size 
Wells' 
Criteria 
Prospective before-and-
after intervention study 
[156] 
Public-sector tertiary-
level and referral 
teaching hospital in 
South Africa 
Efficiency of CTPA 
utilisation 
17.4% vs 30.7% 
(p=0.036) 
Inappropriate CTPA 
scans 
82.6% vs 69.3% 
(p=0.015) 
MEWS 
Prospective before-and-
after intervention study 
[166] 
A University Hospital, in 
Belgium 
Frequency of patient 
observation 
0.99 vs 1.07 (p=0.005) 
Serious adverse events 
after ICU discharge 
5.7% vs 3.5% 
Prospective before-and-
after intervention study 
[167] 
 
The department of 
intensive care medicine, 
at a tertiary referral 
hospital in Brisbane, 
Australia 
Vital signs 
documentation after ICU 
discharge 
210% (95% CI 148, 288%, 
p <0.001). 
Vital signs 
documentation before 
unplanned ICU 
admissions 
44% (95% CI, 3, 102%, p 
= 0.035). 
Retrospective analysis 
of prospectively 
collected data before-
and-after intervention 
study [168] 
The department of 
perioperative and 
critical care at a 
university teaching 
hospital in the United 
Kingdom 
Cardiac arrest calls 0.2% vs 0.4% (p<0.0001) 
Patients admitted to ICU 2% vs 3% (p=0.004) 
In-hospital mortality of 
cardiac arrest patients 
42% vs 52% (p=0.05) 
Ottawa 
Knee Rule 
Nonrandomised 
controlled trial with 
before-after & 
concurrent controls 
[170] 
The Emergency 
departments of two 
teaching and two 
community hospitals in 
Canada 
Reduced time spent by 
patient 
85.7 minutes vs 118.8 
minutes 
Cost savings per patient US $80 vs US $183 
Nonrandomised 
controlled trial with 
before-after & 
concurrent controls 
[171] 
The Emergency 
departments of an 
academic and a 
community hospital in 
Canada. 
Reduced proportion of 
knee injury patients 
referred to radiology 
77.6% vs 57.1% 
Cost savings per patient 
$31 (95% CI, 22 to 44) to 
$34 (95% CI, 24 to 47). 
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Study Selection Process 
 
MEDLINE 
Identified 
Studies = 522
Studies After Duplicates 
Removed (n=831)
EMBASE 
Identified 
Studies = 287
CINAHL 
Identified 
Studies = 166
Google Scholar 
Identified 
Studies = 693
Studies Screened: Titles & 
Abstracts (n=831)
Studies Excluded (n=647): 
Not Relevant to the Topic
Studies Evaluated for 
Eligibility: Full Text (n=184)
Studies Included (n=50)
Studies Excluded (n=134):
1) Not discussing predictive 
tools, CDS systems, or health 
information systems. 2) not 
describing approaches, 
methods, or processes of 
evaluation. 3) not describing 
phases of evaluation. 4) not 
describing criteria or 
measures used in the 
evaluation.
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Figure 3: Study Selection for the Focused Review of Literature 
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Searching the Literature for Published Evidence on Predictive Tools 
 
Using Search Databases; 
MEDLINE, EMBASE, CINAHL 
and Google Scholar to 
Identify the Predictive Tools
Searching Studies Citing 
Primary Studies of Predictive 
Tool, Referring to the Name 
of the Tools, or the Authors
Secondary Studies Reporting 
Predictive Tools (n=6,852)
S
t
e
p
 
1
S
t
e
p
 
2
Tertiary Studies Related to 
Predictive Tools (n=3,416)
Searching Secondary Studies 
References & Studies Citing 
Secondary Studies
Primary Studies Developing 
the Predictive Tools (n=7)
S
t
e
p
 
3
S
t
e
p
 
4
Screening All Primary, 
Secondary, and Tertiary 
Studies to Include only 
Eligible Evidence
Examining Eligible Evidence 
and Assigning Grades to the 
Predictive ToolsS
t
e
p
 
5
Eligible Evidence Including 
Studies Discussing and 
Reporting the Development, 
Validation, Implementation 
or Evaluation of the Five 
Predictive Tools (n=63)
 
Figure 4: Searching the Literature for Published Evidence on Predictive Tools 
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The Mixed Evidence Protocol 
 
Based on Evidence Matching, 
Quality of Studies, and 
Reported Conclusions
Predictive Performance, 
Potential Effect, Usability, or 
Post-Implementation Impact
Sample Size, Data Collection, 
Study Methods, Credibility of 
Institute/Authors
Predictive Task, Intended Use 
& Users, Clinical Specialty, 
Healthcare Settings, Target 
Population, Age Group
Step 1
Class A
Step 2
Matching Not Matching
Class B Class C
Evidence Matching Tool 
Specifications?
Evidence Quality
Evidence Conclusion on 
Reported Criteria
Mixed Evidence from 
Multiple Studies
Matching 
Evidence of 
High Quality
Matching Evidence of Low 
Quality OR Non-Matching 
Evidence of High Quality
Non-Matching 
Evidence of 
Low Quality
Step 3
Mixed Evidence 
Supporting 
Positive Conclusion
Mixed Evidence 
Supporting 
Negative Conclusion
Positive Negative
Deciding the Overall 
Direction of Evidence
Step 4
 
Figure 5: The Mixed Evidence Protocol 
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The mixed evidence protocol is based on four steps. Firstly, it considers the degree of 
matching between the evaluation study conditions and the original tool specifications, in 
terms of the predictive task, outcome, intended use and users, clinical specialty, 
healthcare settings, target population, and age group. Secondly, it considers the quality 
of the study, in terms of sample size, data collection, study methods, and credibility of 
institute or authors. Based on these two criteria, the studies in the mixed evidence on the 
tool are classified into 1) Class A: matching evidence of high quality, 2) Class B: matching 
evidence of low quality or non-matching evidence of high quality, and 3) Class C: non-
matching evidence of low quality. Thirdly, it considers the evidence conclusion on the 
reported evaluation criteria; the predictive performance, potential effect, usability, and 
post-implementation impact. In the fourth step, studies evaluating predictive tools in 
closely matching conditions to the tool specifications and providing high quality 
evidence, Class A, are considered first; taking into account their conclusions on the 
evaluation criteria in deciding the overall direction of evidence. On the other hand, 
studies evaluating predictive tools in different conditions to the tool specifications and 
providing low quality evidence, Class C, are considered last. The conclusion of one study 
in Class A is considered a stronger evidence than the conflicting conclusions of any 
number of studies in Class B or C, and the overall direction of the evidence is decided 
towards the conclusion of the study of Class A. When multiple studies of the same class; 
for example Class A, report conflicting conclusions, then we compare the number of 
studies reporting positive conclusions to those reporting negative conclusions and the 
overall direction of the evidence is decided towards the conclusions of the larger group. 
If the two groups are of the same size, then we check if there are more studies in other 
classes, if not then we examine the reported evaluation criteria and their values in the 
two groups of studies. 
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Performance Figures of Predictive Tools 
 
 
Figure 6: Reported C-Statistic of LACE Index, Centor Score, Wells Criteria and MEWS 
